Transcriptional regulation of the murine 3' IgH enhancer by OCT-2.
Targeted disruption of either of the B cell-specific transcription factors Oct-2 or OCA-B/BOB-1/OBF-1 dramatically affects B cell terminal differentiation. The 3' enhancer of immunoglobulin heavy chain (IgH) locus is important for transcription of the locus in terminal plasma cells. Allele-specific suppression of mutant Oct-2 binding sites in this enhancer by a variant Oct-2 protein revealed that in a mature B cell line this enhancer was specifically dependent upon Oct-2, as contrasted to the closely related Oct-1 transcription factor. Phosphorylation of the Oct-2 protein was important for this activation and was synergistic for coactivation by the OCA-B factor. These results indicate that Oct-2 and OCA-B interact with the 3' enhancer in regulation of the IgH locus during B cell activation.
Tang
H
H
Center for Cancer Research, Massachusetts Institute of Technology, Cambridge 02139, USA.
Sharp
P A
PA
D020413:3' Untranslated Regions; D000483:Alleles; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D004247:DNA / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D004742:Enhancer Elements, Genetic; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000502:physiology*; D019833:Genistein / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007143:Immunoglobulin Heavy Chains / Q000235:genetics*; D007546:Isoquinolines / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000235:genetics*; D051379:Mice; D018345:Mice, Knockout; D016297:Mutagenesis, Site-Directed; D050813:Octamer Transcription Factor-2; D010766:Phosphorylation; D011485:Protein Binding; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D011499:Protein Processing, Post-Translational; D017434:Protein Structure, Tertiary; D011725:Pyridines / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000502:physiology; D019311:Staurosporine / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013449:Sulfonamides; D015534:Trans-Activators / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D014157:Transcription Factors / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D015533:Transcriptional Activation; D014162:Transfection
D020413:3' Untranslated Regions; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors; D007093:Imidazoles; D007143:Immunoglobulin Heavy Chains; D007546:Isoquinolines; D008070:Lipopolysaccharides; D050813:Octamer Transcription Factor-2; C490424:Pou2af1 protein, mouse; C489206:Pou2f2 protein, mouse; D011725:Pyridines; D011993:Recombinant Fusion Proteins; D013449:Sulfonamides; D015534:Trans-Activators; D014157:Transcription Factors; D004247:DNA; C043204:N-(2-guanidinoethyl)-5-isoquinolinesulfonamide; D019833:Genistein; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C; D019311:Staurosporine; C093642:SB 203580